Takeda Announces Closing of Strategic Partnership with Innovent Biologics for Next-Gen Investigational Oncology Medicines December 9, 2025
Additional Positive LP-184 Ph 1a Results Reported Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients December 9, 2025
Updated Efficacy Data from Ph 1/2 Transtar102 Trial of Osemitamab + Nivolumab and CAPOX in 1L G/GEJ Cancer Presented December 9, 2025
Imfinzi approved in the US as perioperative immunotherapy for patients with early gastric/GEJ cancers December 2, 2025
Positive HERIZON-GEA-01 Ph 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted New SOC in 1L HER2+ve LA/M Gastroesophageal Adenocarcinoma November 24, 2025
Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need November 24, 2025
FDA aligned on the design of pivotal study of pelareorep + SOC for 1L treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) November 24, 2025
NDA accepted; PDUFA Date announced for n.c.a. 177Lu-edotreotide (ITM-11) in GEP-NETs November 18, 2025
BostonGene and Kyoto University to develop advanced biological signatures to enhance targeted treatment strategies for ESCC November 18, 2025
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology November 18, 2025
Positive Results Reported from Bezuclastinib PEAK Ph 3 Trial in Gastrointestinal Stromal Tumors (GIST) November 18, 2025
MHRA Approves CTA for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) November 18, 2025
First Patient Dosed in Randomized Dose Optimization Cohort of Ph 2 Study of Muzastotug + KEYTRUDA in MSS-CRC November 10, 2025
FAILED TRIAL: Ph 3 LEAP-012 trial of KEYTRUDA + LENVIMA + TACE combo in HCC patients did not achieve statistical significance for OS vs TACE alone November 4, 2025
First patient dosed in the SPaCE-MT trial of MT-302 with CAPOX with or without nivolumab or trastuzumab in 1L advanced gastroesophageal cancer November 4, 2025
Updated results from GOBLET study of pelareorep + Tecentriq in patients with ≥2L metastatic SCAC announced November 4, 2025
